NASDAQ:CLVSClovis Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clovis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.61 -0.08 (-1.20 %) (As of 07/3/2020 10:09 AM ET) Add Compare Share Today's Range$6.49Now: $6.61▼$6.8450-Day Range$6.48MA: $7.29▼$9.6952-Week Range$2.93Now: $6.61▼$17.37Volume3.34 million shsAverage Volume4.92 million shsMarket Capitalization$508.31 millionP/E RatioN/ADividend YieldN/ABeta2.51 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Read More Beat the Market (BTM) Rank™ 4.1 Analyst's Opinion Consensus RatingClovis Oncology has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 5 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.14, Clovis Oncology has a potential upside of 129.1% from its current price of $6.61.Amount of Analyst CoverageClovis Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesClovis Oncology has received 566 “outperform” votes. (Add your “outperform” vote.)Underperform VotesClovis Oncology has received 551 “underperform” votes. (Add your “underperform” vote.)Community SentimentClovis Oncology has received 50.67% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote “Outperform” if you believe CLVS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldClovis Oncology does not currently pay a dividend.Dividend GrowthClovis Oncology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,483.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Clovis Oncology is held by insiders.Percentage Held by Institutions44.23% of the stock of Clovis Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clovis Oncology are expected to grow in the coming year, from ($4.22) to ($2.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clovis Oncology is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clovis Oncology is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLVS Previous Symbol CUSIP18946410 CIK1466301 Webwww.clovisoncology.com Phone303-625-5000Debt Debt-to-Equity RatioN/A Current Ratio2.47 Quick Ratio2.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$143.01 million Price / Sales3.55 Cash FlowN/A Price / Cash FlowN/A Book Value($3.17) per share Price / Book-2.09Profitability EPS (Most Recent Fiscal Year)($7.60) Net Income$-400,420,000.00 Net Margins-271.13% Return on EquityN/A Return on Assets-62.01%Miscellaneous EmployeesN/A Outstanding Shares76,900,000Market Cap$508.31 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:CLVS Rates by TradingView Receive CLVS News and Ratings via Email Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter. Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions How has Clovis Oncology's stock been impacted by COVID-19 (Coronavirus)? Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLVS stock has increased by 7.1% and is now trading at $6.61. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Clovis Oncology? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Clovis Oncology. When is Clovis Oncology's next earnings date? Clovis Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Clovis Oncology. How were Clovis Oncology's earnings last quarter? Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($1.28) EPS for the quarter, hitting analysts' consensus estimates of ($1.28). The biopharmaceutical company earned $42.56 million during the quarter, compared to analysts' expectations of $41.80 million. View Clovis Oncology's earnings history. What price target have analysts set for CLVS? 12 equities research analysts have issued 1 year target prices for Clovis Oncology's stock. Their forecasts range from $4.00 to $36.00. On average, they expect Clovis Oncology's share price to reach $15.14 in the next year. This suggests a possible upside of 129.1% from the stock's current price. View analysts' price targets for Clovis Oncology. What are Wall Street analysts saying about Clovis Oncology stock? Here are some recent quotes from research analysts about Clovis Oncology stock: 1. According to Zacks Investment Research, "Clovis reported mixed fourth-quarter results, wherein earnings missed estimates but revenues beat the same. Market share of Clovis’ Rubraca in the ovarian cancer PARP inhibitor market improved in 2019. Approval in second-line maintenance setting for ovarian cancer irrespective of the BRCA-mutation is boosting revenues. Successful development of Rubraca in several ongoing studies, targeting different types of ovarian cancer patients and potential approval for prostate cancer indication are likely to boost the drug’s prospects. The company is actively working on expanding the label of Rubraca. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several others under development. Shares have underperformed the industry in the past year." (4/8/2020) 2. HC Wainwright analysts commented, "Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business." (7/3/2019) Has Clovis Oncology been receiving favorable news coverage? Headlines about CLVS stock have been trending negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Clovis Oncology earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Clovis Oncology. Who are some of Clovis Oncology's key competitors? Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Clovis Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Alibaba Group (BABA) and Exelixis (EXEL). Who are Clovis Oncology's key executives? Clovis Oncology's management team includes the following people: Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51) What is Clovis Oncology's stock symbol? Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS." How do I buy shares of Clovis Oncology? Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Clovis Oncology's stock price today? One share of CLVS stock can currently be purchased for approximately $6.61. How big of a company is Clovis Oncology? Clovis Oncology has a market capitalization of $508.31 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis. What is Clovis Oncology's official website? The official website for Clovis Oncology is www.clovisoncology.com. How can I contact Clovis Oncology? Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
